Adamas Pharmaceuticals - ADMS Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMS, but not buy additional shares or sell existing shares.
View ADMS analyst ratings or view top-rated stocks.

6 brokers have issued 12 month price objectives for Adamas Pharmaceuticals' shares. Their ADMS share price forecasts range from $8.00 to $9.10. On average, they anticipate the company's share price to reach $8.53 in the next year. This suggests a possible upside of 3.8% from the stock's current price.
View analysts price targets for ADMS or view top-rated stocks among Wall Street analysts.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) issued its quarterly earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to analysts' expectations of $25.07 million.

2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

One share of ADMS stock can currently be purchased for approximately $8.22.

Adamas Pharmaceuticals (NASDAQ:ADMS) has a market capitalization of $376.37 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57,400,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

The company employs 138 workers across the globe.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The official website for the company is www.adamaspharma.com. The specialty pharmaceutical company can be reached via phone at (510) 450-3500, via email at ir@adamaspharma.com, or via fax at 510-428-0519.